The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

OBJECTIVE: The aim of this study was to evaluate the budget impact of introducing tildrakizumab for moderate-to-severe plaque psoriasis from a US health plan perspective. METHODS: A budget impact model estimated costs before and after the adoption of tildrakizumab to a hypothetical US health plan wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrico, Justin, Zhao, Yang, Jia, Xiaoying, Brodtkorb, Thor-Henrik, Mendelsohn, Alan, Lowry, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688845/
https://www.ncbi.nlm.nih.gov/pubmed/32219733
http://dx.doi.org/10.1007/s41669-020-00208-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688845/
https://www.ncbi.nlm.nih.gov/pubmed/32219733
http://dx.doi.org/10.1007/s41669-020-00208-9

Ejemplares similares